MANKIND

Mankind Pharma Share Price

 

 

Invest in Mankind Pharma with 3.51X leverage

Invest with MTF
Mankind Pharma live price: ₹2237.7. It opened at ₹2,190 vs previous close ₹2,163; intraday high/low: ₹2,249/₹2,169. The 50 & 200 DMA stand at ₹2,159.36/₹2,293.91.

Mankind Pharma Performance

  • Low
  • ₹2,169
  • High
  • ₹2,249
  • 52 Week Low
  • ₹2,012
  • 52 Week High
  • ₹2,717
  • Open Price₹2,190
  • Previous Close₹2,163
  • Volume1,043,920
  • 50 DMA₹2,159.36
  • 100 DMA₹2,215.49
  • 200 DMA₹2,293.91

Investment Returns

  • Over 1 Month + 7.48%
  • Over 3 Month + 2.63%
  • Over 6 Month -13.58%
  • Over 1 Year -3.38%

Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!

Invest Now

Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 51.9
  • PEG Ratio
  • -4
  • Market Cap Cr
  • 92,373
  • P/B Ratio
  • 5.9
  • Average True Range
  • 60.74
  • EPS
  • 45.01
  • Dividend Yield
  • 0
  • MACD Signal
  • 14.5
  • RSI
  • 59.18
  • MFI
  • 63.97

Mankind Pharma Financials

Mankind Pharma Technicals

EMA & SMA

Current Price
₹2,237.70
+ 74.4 (3.44%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 13
  • 20 Day
  • ₹2,159.55
  • 50 Day
  • ₹2,159.36
  • 100 Day
  • ₹2,215.49
  • 200 Day
  • ₹2,293.91

Resistance and Support

2218.73 Pivot Speed
  • R3 2,348.37
  • R2 2,298.83
  • R1 2,268.27
  • S1 2,188.17
  • S2 2,138.63
  • S3 2,108.07

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Mankind Pharma Ltd. is one of India’s largest pharmaceutical companies, providing a wide range of affordable medicines in areas like antibiotics, cardiovascular, gastrointestinal, and dermatology. It also manufactures over-the-counter (OTC) products, catering to domestic and global markets.

Mankind Pharma Ltd has an operating revenue of Rs. 13,914.08 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 21% is great, ROE of 13% is good. The company has a reasonable debt to equity of 39%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 63 which is FAIR indicating the recent price performance, Buyer Demand at D- which indicates heavy supply, Group Rank of 89 indicates it belongs to a poor industry group of Medical-Products and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Mankind Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-03 Quarterly Results
2025-11-06 Quarterly Results
2025-07-31 Quarterly Results & Interim Dividend
2025-05-21 Audited Results
2025-01-23 Quarterly Results
Date Purpose Remarks
2025-08-08 INTERIM Rs.1.00 per share(100%)Interim Dividend
View Mankind Pharma Dividend History Arrow

Mankind Pharma F&O

Mankind Pharma Shareholding Pattern

72.66%
9.3%
1.12%
11.34%
1.52%
4.06%

Mankind Pharma FAQs

Mankind Pharma share price is ₹2,237 As on 11 March, 2026 | 01:45

The Market Cap of Mankind Pharma is ₹92373.4 Cr As on 11 March, 2026 | 01:45

The P/E ratio of Mankind Pharma is 51.9 As on 11 March, 2026 | 01:45

The PB ratio of Mankind Pharma is 5.9 As on 11 March, 2026 | 01:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23